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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Does
the addition of muramyl tripeptide to chemotherapy improve overall survival for patients with
osteosarcoma?”
STUDY DESIGN: Review of three English language primary randomized controlled trials
published between 2005 and 2009.
DATA SOURCES: Randomized controlled trials evaluating the addition of muramyl tripeptide
(MTP) to chemotherapy for patients with osteosarcoma were found using Medline/PubMed
databases.
OUTCOMES MEASURED: Event-free survival (EFS) and overall survival were the outcome
measures used to determine the effectiveness of the additional chemotherapy treatment in
osteosarcoma patients. EFS was defined as the time from entry until an adverse event or last
patient contact. Overall survival was defined as the time from entry until death or last patient
contact.
RESULTS: Three randomized controlled trials were included in this review. A study by Meyers
et al could not be analyzed according to its original factorial design due to an interaction between
the study interventions. However, a follow up by Meyers et al, reported no evidence of
statistically significant interaction between study interventions. The results demonstrated that the
addition of MTP to chemotherapy resulted in a trend toward better EFS (p=.08), and improved 6year overall survival from 70% to 78% (p=.03). Another study, by Chou et al, looked at the
metastatic cohort from Intergroup Study 0133 in isolation, and found that the 5-year EFS for
patients who received liposomal MTP was 42% versus 26% for those who did not (RR 0.72;
p=.23; 95% CI). The 5-year OS for patients who received MTP versus no MTP was 53% and
40% respectively (RR 0.72; p=0.27; 95% CI).
CONCLUSION: Based on these three trials, it is inconclusive if the addition of MTP to
chemotherapy improves overall survival in patients with osteosarcoma. The addition of MTP to
chemotherapy has demonstrated a statistically significant improvement in overall survival, as
well as a trend toward better EFS, but only in non-metastatic cohorts. The addition of MTP to
chemotherapy did not achieve a statistically significant improvement in EFS or overall survival
for those with metastatic osteosarcoma. Although the pattern of outcome was similar in all three
studies, further research should be aimed at determining a particular chemotherapy plus MTP
regimen and a specific patient population for which MTP is most effective.
KEY WORDS: Osteosarcoma; Chemotherapy; Survival
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INTRODUCTION
Osteosarcoma is the most common malignant primary bone tumor in children and
adolescents1. It is a malignant tumor of the bone in which the proliferating cells produce osteoid
tissue or immature bone2. The peak occurrence during the adolescent growth spurt indicates that
a relationship exists between rapid bone growth and malignant transformation3. Osteosarcoma
occurs most frequently at sites where the greatest increase in length and size of bone occurs, with
the metaphyses of long bones such as the femur being most commonly affected3.
The incidence of osteosarcoma is approximately 4.8 per million children younger than 20
years of age1. The annual incidence rate of osteosarcoma is quite variable. Incidence rate by age
is approximately 0.3 per million in children under the age of 5 years, 2.8 per million between the
ages of 5 and 9 years, 8.3 per million between the ages of 10 and 14 years, and 9.4 per million
between the ages of 15 and 19 years1. Approximately 400 new cases are reported each year in
those under the age of 20 years in the United States1.
While an exact cost approximation has not been identified, the evaluation and treatment
of osteosarcoma is quite complex. Curative treatment approach to osteosarcoma involves both
pre and post-op chemotherapy regimens lasting at least one year, surgical reconstructive
procedures, frequent imaging modalities, lengthy inpatient hospital stays and complex
rehabilitation programs. In 2007, approximately 37.1 million dollars was spent on osteosarcoma
research4.
The etiology of osteosarcoma is unknown. The only well documented etiology is an
environmental factor which is ionizing radiation exposure.1,5. Radiation is implicated in
approximately 2% of osteosarcomas. Research suggests that a viral etiology may be responsible
for bone sarcomas as evidenced by induction of cancer cells in response to viral factors or cell-
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free extracts of human osteosarcomas in the animal model1,5. A genetic predisposition of
osteosarcoma has been suggested, as several families have been identified to have multiple
members with osteosarcoma5. The strongest genetic predisposition has been found in patients
with retinoblastoma. In the hereditary form of this disorder, germline mutations of the
retinoblastoma gene are common and most likely account for the increased frequency of
secondary cancers in this population1. In addition, germline mutations in the p53 gene can lead
to a high risk of developing malignancies such as osteosarcoma, which has been described as the
Li-Fraumeni syndrome1,5. Individuals with syndromes such as Rothmund-Thomson syndrome
and Werner and Bloom syndrome are also at high risk of developing osteosarcoma1. A history of
disorders of bone metabolism, such as Paget disease and fibrous dysplasia, are also known
predisposing factors in the development of osteosarcoma1.
Early research reported that adjuvant chemotherapy had activity against both relapsed
and metastatic osteosarcoma, demonstrating improved disease free survival rates 1,3.
Chemotherapy is often administered prior to definitive surgery promoting an early attack on
micrometastatic disease and tumor shrinkage, which aids in a limb preserving procedure3. The
cytotoxic agents that have been shown to demonstrate the greatest efficacy in the treatment of
osteosarcoma include high dose methotrexate, cisplatin, doxorubicin, and ifosfamide 1,3,6.
Complete surgical resection of primary and metastatic disease is the cornerstone for
successful treatment of osteosarcoma1. Surgical management involves the complete resection of
the tumor with a margin of uninvolved tissue and soft-tissue reconstruction1,3. Post surgical
chemotherapy is typically continued until the patient has received 1 full year of treatment3.
Osteosarcomas are highly radioresistant, thus radiotherapy has no role in its management3.

Jones, Muramyl Tripeptide & Osteosarcoma

3

The addition of MTP to chemotherapy regimens may provide additional benefit to and
improve the overall survival of patients newly diagnosed with osteosarcoma6,7,8. Muramyl
tripeptide (MTP) phosphatidylethanolamine (MTP-PE) is a synthetic lipophilic analog of
muramyl dipeptide, and is a nonspecific immune modulator that is a synthetic analogue of a
component of bacterial cell walls6,7,8. MTP has been encapsulated in liposomes to target delivery
to monocytes and macrophages to activate them to become tumoricidal6,7,8. Preclinical studies
have confirmed antitumor effects of MTP in rodents and canines with osteosarcoma 6.7,8.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Does the
addition of muramyl tripeptide to chemotherapy improve overall survival for patients with
osteosarcoma?”
METHODS
Meyers et al6, conducted a prospective randomized phase 3 trial for the treatment of
newly diagnosed osteosarcoma in patients ≤ 30 years old. This study compared the standard 3drug chemotherapy regimen (doxorubicin, cisplatin, and high-dose methotrexate) with the
addition of ifosfamide6. Additionally, patients were randomly assigned to receive MTP in
conjunction with the assigned chemotherapy6. The outcome measure used was event-free
survival (EFS)6.
With additional follow up and review of the previously mentioned trial, a report and
update of the results were presented in a subsequent study by the same authors. The primary end
point for this analysis included both EFS and overall survival7. In an additional study, Chou et
al8 reported results for only those patients with metastatic disease who were enrolled in this trial,
evaluating both EFS and overall survival.
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A detailed search was completed using Medline/PubMed databases with the key words:
“osteosarcoma”, “chemotherapy”, and “survival”. Articles selected were limited to English
language peer reviewed publications between 2005 and 2009. The criterion used for selection
was based on their relevance and the importance of the outcome to the patient (POEMS).
Inclusion criteria were randomized controlled trials based on patient oriented outcomes. Studies
excluded were those that included patients over the age of 30 years, patients who received prior
chemotherapy or radiation, and individuals with non-resectable disease. Refer to Table 1 for
further information regarding demographics and study characteristics. Relative risk and hazard
ratios were evaluated to determine the relationship between treatment and overall and event free
survival. 95% confidence intervals set and a p value of .05 was used to determine statistical
significance between the variables of treatment and event free and overall survival.
Table 1: Demographics and Characteristics of Included Studies
Study

Type

Age

RCT

#
Pts
677

Meyers6,
2005

Meyers7,
2008

RCT

662

0-30

0-30

Inclusion
Criteria
Pts with
histologically
confirmed, highgrade,
intramedullary
osteosarcoma.
Adequate renal,
hepatic, and
cardiac function.

Pts with
histologically
confirmed highgrade
intramedullary
osteosarcoma.

Exclusion
Criteria
Pts who received
prior chemo or
radiation.
At Pediatric
Oncology Group
institutions, pts
with clinically
detectable
metastatic disease
were ineligible.
Pts with > 30 d
elapsed btwn
diagnostic biopsy
and enrollment.
Clinically
detectable
metastatic
disease.
Non-resectable
disease.

W/D

Interventions

0

Addition of MTP to
cisplatin, doxorubicin,
and high dose
methotrexate
(HDMTX) or cisplatin,
doxorubicin, HDMTX,
and ifosfamide after
tumor resection.

0

Addition of MTP to
cisplatin, doxorubicin,
and high dose
methotrexate
(HDMTX) or cisplatin,
doxorubicin, HDMTX,
and ifosfamide after
tumor resection.
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Chou8,
2009

RCT

91

0-30

Pts with
histologically
confirmed highgrade
intramedullary
osteosarcoma.
Pts with at least
one site of
metastasis.

Pts with
clinically
detectable
metastatic disease
were not eligible
at Pediatric
Oncology Group
institutions
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Addition of MTP to
cisplatin, doxorubicin,
and high dose
methotrexate
(HDMTX) or cisplatin,
doxorubicin, HDMTX,
and ifosfamide after
tumor resection.

OUTCOMES MEASURED
The outcomes measured were those of patient oriented evidence that matters (POEMS),
which includes event free survival (EFS), defined as the time from entry until an adverse event
or last patient contact6,7,8. EFS after surgery was defined from the start of the first course of
maintenance therapy until adverse event or last patient contact6,7,8. Adverse events included
progression of disease, diagnosis of a second malignant neoplasm, or death before disease
progression or second malignant neoplasm 6,7. However, Chou et al8, did not consider
progression of the disease after induction an event, allowing these patients to remain in the study.
Overall survival was a common outcome used by Meyers et al7 and Chou et al8, which was
defined as the time from entry into the trial until death or last patient contact.
EFS and overall survival were estimated using the Kaplan-Meier method6,7,8. The logrank test was used to assess the statistical significance of the comparisons of risk for adverse
event6,7,8. The stratified log-rank test was used to evaluate outcomes measured from the time of
enrollment and involving randomized regimens6,7,8. A relative hazards regression model with the
characteristic of interest as the only variable in the model, was used to set up confidence
intervals (CIs) and evaluate relative risk6,7,8. In Meyers et al7 and Chou et al8, interaction
between chemotherapy and biological agent was assessed using the relative hazards regression.
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RESULTS
Three randomized controlled trials are analyzed in this review. The primary end point for
the analysis of these studies was EFS and overall survival. All results were presented in
dichotomous form.
Meyers et al6, reported that for patients without metastasis, EFS was 70% at 3 years and
63% at 5 years from study entry6. Original study design included a 2 X 2 factorial design for
analysis. However, secondary to an interaction between the two study interventions this model
was not appropriate for analysis. Regimen A- (cisplatin, doxorubicin, and HDMTX) was
considered the standard arm of the trial6. Regimen B- consisted of cisplatin, doxorubicin, and
HDMTX with the addition of ifosfamide6. Regimen B+ consisted of cisplatin, doxorubicin, and
HDMTX with the addition of ifosfamide and MTP6. These two regimens were compared to the
standard arm in order to evaluate an interaction between treatments6. Regimen B- resulted in a
decreased EFS, while regimen B+ resulted in increased EFS6. Detailed results of the four study
arms are displayed in Table 2.
Table 2-Relative Risk of Adverse Event According to Randomized Regimen
Randomized
# pts
RR
95% CI
Regimen
AA+
ABAB+

172
168
172
167
172
170

1.0
1.0
1.0
1.3
1.0
0.78

-0.71 to 1.5
-0.93 to 1.9
-0.54 to 1.2

P-value
.88
.12
.22

Meyers et al7, conducted a follow up investigation of the addition of MTP to standard
chemo based on their previous results and interactions observed. The conclusion of the previous
study did not change, however, based upon what was observed the authors were able to expand
on the results and interactions observed. Follow up analysis of the outcome for EFS and overall
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survival did not identify a statistically significant interaction between the two interventions
(p=.102)7.
Meyers et al, reported an EFS of 66% at 4 years and 64% at 6 years from study entry7.
When MTP was added to chemotherapy, EFS improved, but without statistical significance. For
all patients who were not assigned to receive MTP, 6 year EFS was 61%7. In patients assigned
to receive MTP the 6-year EFS was 67% (p=.08)7. Additional results are displayed in Table 3.
The addition of MTP to chemotherapy provided an enhanced overall survival. Overall
survival was reported as 81% at four years and 74% at six years from entry into the study7. The
addition of MTP to chemotherapy resulted in improvement in 6-year overall survival from 70%
to 78% (p=.03; RR=0.71)7. The authors believe that the improvement in overall survival, with
median follow up of 7.7 years, can be attributed to the randomized addition of MTP to initial
chemotherapy treatment7. (Table 3)
As displayed in Table 4 the hazard ratio for EFS for patients who received MTP was
0.80 (95% CI, 0.62 to 1.0). This does not meet an established p< .05 level of significance
(p=.08)7. The relative risk of death for patients randomly assigned to receive MTP is 0.71 (95%
CI, 0.52 to 0.96; p= .03)7. Both chemotherapy regimens were associated with the same risk of
death (p=.83)7.
Table 3- EFS and Overall Survival According to Treatment Regimen
Treatment Regimen
EFS Probability (%)
Survival Probability
4 year
6year
4 year
6 year
All patients
Regimen A :Without MTP
With MTP
Regimen B: Without MTP
With MTP
Regimen A with or without MTP
Regimen B with or without MTP
Chemotherapy: Without MTP
With MTP

66
66
65
60
74
65
67
63
69

64
64
63
58
71
63
64
61
67

81
78
82
77
86
80
82
78
84

74
71
75
70
81
73
75
70
78
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Table 4- Analysis of Interaction of MTP
Hazard Ratio
Event Free Survival
Regimen A
Regimen B
All patients
Overall Survival
Regimen A
Regimen B
All patients

8

95% CI

0.99
0.65
0.80

0.69 to 1.4
0.45 to 0.93
0.62 to 1.0

0.76
0.66
0.71

0.49 to 1.2
0.43 to 1.0
0.52 to 0.96

In the study performed by Chou et al8, 91 patients from Intergroup Study 0133 with
metastatic disease at initial diagnosis were analyzed. As of August 2005, the 5-year EFS for this
entire cohort of patients was 34% and the 5-year overall survival was 47%8. Further detail
regarding EFS and overall survival on each chemotherapy regimen is provided in Table 5. For
EFS, no statistical difference was identified among all regimens (log-rank= 0.55)8. For overall
survival there was no statistical difference among the regimens (log-rank= 0.60)8. The relative
risk for adverse event associated with assignment to receive MTP was 0.728. The relative risk
for death associated with assignment to receive MTP was 0.728. Further detail regarding relative
risk of death and relative risk of adverse event is provided in Table 6.
Table 5- EFS and Overall Survival According to Treatment Regimen
5 Year EFS
95% CI
5 Year Overall
Survival
All
Regimen A
without MTP
Regimen A with
MTP
Regimen B
without MTP
Regimen B with
MTP

95% CI

34%

24 to 45

47%

35 to 58

29%

11 to 51

53%

28 to 73

41%

21 to 60

50%

26 to 69

23%

8 to 43

30%

13 to 50

44%

23 to 64

57%

33 to 75
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Table 6-Relative Risks Based on Treatment Regimen
Relative Risk of Death
Regimen A
Regimen B
MTP
No MTP

Relative Risk of Adverse
Event

1.0
1.1
0.72
1.0

1
1.07
0.72
1.0

Treatment effects of all three studies are displayed in Table 7. Number needed to treat
(NNT) was calculated to describe the number that would need to be treated in order to prevent
one additional adverse outcome as compared with the standard chemotherapy regimen of
cisplatin, doxorubicin, and HDMTX. The absolute benefit increase (ABI) represents the actual
increase in positive outcomes between all treatment regimens and the control regimen. The
relative benefit increase (RBI) represents the increased chance of positive outcome in the
treatment regimens compared to the chance of positive outcomes in the control regimen.
Table-7 Comparisons of Dichotomous Data
CER
EER

RBI

ABI

Meyer et al05
42
54
29
12
08
Meyer et al
60
68
13
8
Chou et al
42
54
29
12
CER=Control Event Rate; EER=Experimental Event Rate; RBI=Relative Benefit Increase;
ABI=Absolute Benefit Increase

NNT
9
13
9

Most side effects of the addition of MTP were found to be mild to moderate in nature.
Common side effects observed include: fever, chills, elevation in ALT, infections, anemia, and
stomatitis6. Most patients experienced fewer adverse events with time and subsequent
administration.
DISCUSSION
In the randomized control trial conducted by Meyers et al6, the addition of MTP to a
three-drug chemotherapy regimen including cisplatin, doxorubicin, and high dose methotrexate
had no impact on EFS. However, the addition of MTP to a four-drug chemotherapy regimen

9
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including cisplatin, doxorubicin, high dose methotrexate, and ifosfamide resulted in more
favorable EFS6. Unfortunately, an observed interaction between ifosfamide and MTP
invalidated the factorial design for the analysis of the impact of MTP on EFS. Although
comparison of the four treatment arms showed a possible improvement in EFS with the addition
of MTP to chemotherapy, further clinical and laboratory investigation was required to explain
the interaction between ifosfamide and MTP.
With additional follow-up and further examination of the data reported in Meyers et al6
Intergroup Study 0133, the authors reported additional results and conclusions of this trial. Upon
further exam, there was no statistically significant interaction between study interventions7. The
addition of MTP to chemotherapy resulted in improved 6 year overall survival from 70 to 78%7
which was a statistically significant improvement in overall survival (p=.03). Also, a trend
toward improved EFS for patients with non-metastatic osteosarcoma was observed7.
In the study performed by Chou et al8, patients with metastatic disease enrolled in
Intergroup Study 0133, a trend toward improved EFS and overall survival with the addition of
MTP to chemotherapy was observed, but was not statistically significant. Secondary to the small
number of patients included in the study cohort, precise estimation of treatment effect and
conclusions about the differences between each study arm was not possible. Additional, larger
studies analyzing the effect of MTP to chemotherapy in patients with metastatic disease is
required.
The poor prognosis of patients diagnosed with osteosarcoma emphasizes the need for
new cytotoxic agents to be identified and utilized in treatment. Liposomal MTP-PE is an
immune modulator that has been studied extensively in the treatment of osteosarcoma. In 2009
the European Medicines Agency (EMA) approved the use of MTP as a drug called Mifamurtide
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for the treatment of high-grade, non-metastatic, resectable osteosarcoma in patients aged two to
thirty years9. The FDA denied approval of this drug in 20079. Analysis and further, larger
clinical trials regarding optimal dosing of MTP both before and after tumor resection, as well as
usefulness in metastatic osteosarcoma is required.
CONCLUSION
Based on the analysis of the three trials included in this review, it is inconclusive if the
addition of MTP to chemotherapy improves overall survival in patients with osteosarcoma.
There is a pattern of outcome in favor of this multidrug regimen and results supporting its antitumor effects in patients with non-metastatic osteosarcoma, however it is not clear if the results
are clinically significant enough to warrant making major changes to management of this
disease. Further research should be aimed at inclusion of larger patient populations over longer
periods of time, with use of a single chemotherapy regimen for both metastatic and nonmetastatic patients, and should address the optimal dosing schedule for MTP administration.
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